A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis

Atsushi Kuno, Yuzuru Ikehara, Yasuhito Tanaka, Kiyoaki Ito, Atsushi Matsuda, Satoru Sekiya, Shuhei Hige, Michiie Sakamoto, Masayoshi Kage, Masashi Mizokami, Hisashi Narimatsu

研究成果: Article査読

197 被引用数 (Scopus)

抄録

Although liver fibrosis reflects disease severity in chronic hepatitis patients, there has been no simple and accurate system to evaluate the therapeutic effect based on fibrosis. We developed a glycan-based immunoassay, FastLec-Hepa, to fill this unmet need. FastLec-Hepa automatically detects unique fibrosis-related glyco-alteration in serum hyperglycosylated Mac-2 binding protein within 20 min. The serum FastLec-Hepa counts increased with advancing fibrosis and illustrated significant differences in medians between all fibrosis stages. FastLec-Hepa is sufficiently sensitive and quantitative to evaluate the effects of PEG-interferon-α/ribavirin therapy in a short post-therapeutic interval. The obtained fibrosis progression is equivalent to-0.30 stages/year in patients with sustained virological response, and 0.01 stages/year in relapse/nonresponders. Furthermore, long-term follow-up of the severely affected patients found hepatocellular carcinoma developed in patients after therapy whose FastLec-Hepa counts remained above a designated cutoff value. FastLec-Hepa is the only assay currently available for clinically beneficial therapy evaluation through quantitation of disease severity.

本文言語English
論文番号1065
ジャーナルScientific reports
3
DOI
出版ステータスPublished - 2013

ASJC Scopus subject areas

  • General

フィンガープリント 「A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル